(Q43665499)

25 November 2017

Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

Chin-Hsiao Tseng

1

0 references

language of work or name

English

0 references

publication date

12 November 2013

1 reference

25 November 2017

1 reference

25 November 2017

45

1 reference

25 November 2017

8

1 reference

25 November 2017

539-544

1 reference

International patterns and trends in thyroid cancer incidence, 1973-2002

25 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Diabetes and risk of prostate cancer: a study using the National Health Insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Radiation-induced thyroid cancer: what we have learned from chernobyl

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

Taiwan's new national health insurance program: genesis and experience so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2013.851865

10.3109/07853890.2013.851865

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

24215589